12 recruiting, 11 completed, 11 unknown, 10 terminated. 42 Phase 2, 8 Phase 1, 1 Not applicable, 1 Phase 3.
Follow pemigatinib: new trials by email Literature Review of pemigatinib trials Research Report on pemigatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| PH 2 Pemigatinib in SDH-deficient GIST Pemigatinib - SDH Gene Mutation, Gastrointestinal Stromal Tumor | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 24 | 2026-05-19 | 2026-05-22 |
| A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement Pemigatinib, Durvalumab - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement | Phase 2 | Recruiting | Mehmet Akce | 38 | 2026-01-27 | 2026-10-05 |
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Pemigatinib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University of Utah | 1 | 2025-10-03 | 2026-07-09 |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging - Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Recruiting | Sameek Roychowdhury | 40 | 2025-08-26 | 2026-02-17 |
| Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells Pemigatinib - Solid Tumor, Miscellaneous | Phase 2 | Recruiting | UNICANCER | 40 | 2025-03-27 | 2025-06-05 |
| Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion Pemigatinib, Atezolizumab, Bevacizumab - Advanced Cholangiocarcinoma, FGFR2 Fusion | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 25 | 2024-11-19 | 2026-08-17 |
| Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor Pemigatinib - Urothelial Carcinoma, Breast Neoplasms | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2024-08-15 | 2024-08-13 |
| Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma Pemigatinib and Durvalumab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 38 | 2024-08-01 | 2024-07-31 |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma | Phase 2 | Recruiting | Lund University Hospital | 33 | 2024-06-20 | 2026-08-27 |
| Pemigatinib + Afatinib in Advanced Refractory Solid Tumors Afatinib, Pemigatinib - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 | Recruiting | Massachusetts General Hospital | 32 | 2024-04-17 | 2026-09-23 |
| A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant Pemigatinib - Locally Advanced Unresectable Gastric Cancer | Phase 2 | Unknown | Sun Yat-sen University | 23 | 2023-08-25 | 2023-08-18 |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma Pemigatinib, PD-1 Inhibitors - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2023-07-01 | 2023-06-22 |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors Pemigatinib - Solid Tumor, FGF Receptor Gene Mutation | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 20 | 2023-05-01 | 2023-09-01 |
| Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations Pemigatinib - Gastrointestinal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 100 | 2022-12-02 | 2022-12-15 |
| Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements Pemigatinib - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 2 | Terminated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 | 2022-11-11 | 2025-04-13 |
| A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Pemigatinib Pill - Breast Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2022-09-08 | 2022-09-29 |
| A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy Pemigatinib Pill - Gastrointestinal Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 20 | 2022-08-10 | 2022-09-29 |
| Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas Pemigatinib 4.5 MG - Pancreas Cancer | Phase 2 | Withdrawn | HonorHealth Research Institute | 2022-06-14 | 2023-07-03 |
Showing 20 of 50. Sign in to see all of them.
Cholangiocarcinoma (12) · Acrocephalosyndactylia (6) · Carcinoma, Transitional Cell (5) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3) · Gastrointestinal Neoplasms (3) · Carcinoma (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2)
Incyte Corporation (15) · Academic and Community Cancer Research United (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Dana-Farber Cancer Institute (1) · Eastern Hepatobiliary Surgery Hospital (1) · European Association of Urology Research Foundation (1) · Fondazione per la Medicina Personalizzata (1) · Helsinki University Central Hospital (1) · Hoffmann-La Roche (1) · HonorHealth Research Institute (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Lund University Hospital (1) · M.D. Anderson Cancer Center (1)
United States (24) · China (13) · Italy (13) · France (11) · Germany (11) · Japan (10) · Spain (9) · United Kingdom (8) · Denmark (7) · Belgium (6) · Israel (5) · Netherlands (5) · Austria (4) · Finland (4) · South Korea (4)
Ekaterine Asatiani, MD (2) · Peter Langmuir, MD (2) · Sameek Roychowdhury, MD, PhD (2) · Andrea Botticelli (1) · Andrea Necchi, Dr. (1) · Dae Won Kim, MD (1) · E.E. Voest, prof. (1) · Elie Traer, MD PhD (1) · Erkut Borazanci, MD (1) · Feng Ye, Doctor (1) · HaiTao Wang, Ph.D (1) · Haley Ellis, MD (1)
PMID 41180818, PMID 32203698, PMID 32677452, PMID 34951522, PMID 35086719, PMID 35176457, PMID 35544727, PMID 35598186, PMID 36127767, PMID 36206041, PMID 36870947, PMID 37424386, PMID 37889382, PMID 37934000, PMID 37956738, PMID 38039831, PMID 38630551, PMID 38710951, PMID 39096924, PMID 40515475, PMID 40856555, PMID 41023484, PMID 41678089, PMID 41963505, PMID 41986720, PMID 42223137, PMID 42691436
2016 (3), 2018 (3), P30CA015083 (2), 2017 (1), 2019 (1), 2025 (1)